Company intelligence / Profile preview

Regenerative Medical Solutions

Madison, Wisconsin, United Statesregenmedsolutions.com ↗

Ownership: Private
Employees: ~10
Development stage: Other

Overview

RMS has developed patented methods for differentiating human induced pluripotent stem cells into insulin-producing islet-like clusters. These are being evaluated as both research tools and potential curative therapies for diabetes. The company has had successful preclinical studies and a recent positive FDA meeting but does not yet have published clinical trial results

Therapeutic areas: Endocrinology
Modalities: Induced pluripotent stem cell derived therapyCell therapyBiologic (as a broader category)
Industry: Biotech

Drug pipeline

1 asset

ILC

Preclinical

Partnerships

Collaborations with University of Wisconsin-Madison researchers

Beyond the preview

Go deeper on Regenerative Medical Solutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Regenerative Medical Solutions.

Explore the full profile